Company: INMB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001213900-25-041072
Chunk: 32

Company: Inmune Bio, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 32
---
 product candidates;

    ●
    establish a commercialization infrastructure and scale up our manufacturing and distribution capabilities to commercialize any of our product candidates for which we may obtain regulatory approval;

    ●
    seek to comply with regulatory standards and laws;

    ●
    maintain, leverage and expand our intellectual property portfolio;

    ●
    hire clinical, manufacturing, scientific and other personnel to support our product candidates development and future commercialization efforts;

    ●
    add operational, financial and management information systems and personnel; and

    ●
    incur additional legal, accounting and other expenses in operating as a public company.

23

Results of Operations 

Comparison of the Three Months Ended March
31, 2025 and 2024

The following table summarizes
our results of operations for the periods indicated:

    Three Months Ended March 31,  

    (in thousands) 
    2025  
    2024  
    Change 
  
    Revenues 
    $50  
    $14  
    $36 
  
    Operating expenses: 

    Research and development 
     7,639  
     8,693  
     (1,054)
  
    General and administrative 
     2,316  
     2,338  
     (22)
  
    Total operating expenses 
     9,955  
     11,031  
     (1,076)
  
    Loss from operations 
     (9,905) 
     (11,017) 
     1,112 
  
    Other expense, net 
     166  
     (8) 
     174 
  
    Net loss 
    $(9,739) 
    $(11,025) 
    $1,286 

Revenues

During the three months ended
March 31, 2025 and 2024, the Company sold MSC’s to third-parties and recognized $50,000 and $14,000, respectively, of revenues.

General and Administrative

General and administrative
expenses were approximately $2.3 million during each of the three months ended March 31, 2025 and 2024, respectively.

Research and Development

Research and development expenses
were approximately $7.6 million during the three months ended March 31, 2025, compared to approximately $8.7 million during the three
months ended March 31, 2024. The change in research